Patients like Michael inspire us to continue our mission to make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel. Transcript: Frances Saldana: My name is Frances Saldana and I’m a Huntington’s disease patient advocate.
In an urgent effort to develop a potential vaccine and medicine for COVID-19, a San Francisco drug company on Friday asked residents of Boston and five other US hot spots in the coronavirus epidemic to donate blood if they have recovered from the disease.
Biotech company needs your help with advance research. Vir Biotechnology is looking for patients in San Diego and Los Angeles counties who have recovered from COVID-19 to donate blood to help the company find better ways to diagnose and treat the infection.
Distinguished Pfizer researchers David Beidler and Debra Pittman share their experience in Sickle Cell Disease including: Using longitudinal biomarker data from early clinical development decision in sickle cell disease (SCD) Building the patient perspective into clinical trials: development of the vaso-occlusive crisis (VOC) day endpoint through the use of the electronic patient-reported outcomes (ePRO) Bring it all together in ELIPSIS: a natural history study to evaluate longitudinal changes in ePRO, actigraphy, and biomarkers in SCD patients Transcript Speaker 1: Today.
Sanguine partners with patients and leverages their health data to accelerate your research for their condition. By working together with patients directly, Sanguine is able to perform home visits and to easily retrieve medical records on their behalf. 500+ completed studies.
With more than 40,000 ongoing global clinical trials, COVID-19 will cause immense delays with the advancement of research. For non-invasive biospecimen studies and clinical trials that require test subjects to visit hospitals or clinics for biospecimen collection, will the patients just stop showing up for collection?